CervoMed Inc
CervoMed Inc. is a clinical-stage company focused on developing treatments for age-related neurologic disorders. The Company is developing neflamapimod, an investigational, orally administered small molecule brain penetrant that inhibits p38 mitogen-activated protein kinase alpha. Neflamapimod has the potential to treat synaptic dysfunction, the reversible aspect of the underlying neurodegenerative processes that cause disease in Lewy bodies (DLB) and certain other neurological disorders. It focuses on reducing the impact of inflammation in the brain, or neuroinflammation, which is a key factor in the manifestation of degenerative diseases of the brain, including DLB. Neflamapimod is being evaluated in the Company's ongoing RewinD-LB Trial, a Phase 2b trial in patients with DLB.
Stock Performance Snapshot
Analyst Rating
Analysts recommend buying CervoMed's stock, indicating strong potential for future growth.
Financial Health
CervoMed Inc is generating modest revenue and cash flow, with a stable book value per share.
View more stocks by downloading the app for FREE
It only takes 60 seconds.
Baskets Featuring CRVO
Safer Alzheimer's Treatments
This carefully selected group of stocks represents companies at the forefront of developing safer, more effective Alzheimer's treatments. The FDA's recent approval of improved dosing for breakthrough therapies has created significant new opportunities in this rapidly evolving field.
Published: July 11, 2025
Explore BasketWhy You’ll Want to Watch This Stock
Clinical Milestones Watch
Progress in clinical trials or regulatory approvals can shift prospects materially, though timelines can slip and outcomes remain uncertain.
Capital & Partnerships
Financing, partnerships or licensing deals can extend runway and validate technology, but may dilute shareholders or depend on complex negotiations.
Market & Competition
Adoption, reimbursement and competitive dynamics shape long‑term opportunity; small firms may face resource constraints and regulatory barriers.
Why invest with Nemo?
Zero Commission
Trade stocks, ETFs, and more with zero commission. Keep more of your returns.
Trusted & Regulated
Part of Exinity Group 2015, serving over a million customers globally.
6% Interest on Cash
Earn 6% AER on uninvested cash with daily interest payments.
